HRP20120263T1 - Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje shizofrenije - Google Patents

Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje shizofrenije Download PDF

Info

Publication number
HRP20120263T1
HRP20120263T1 HR20120263T HRP20120263T HRP20120263T1 HR P20120263 T1 HRP20120263 T1 HR P20120263T1 HR 20120263 T HR20120263 T HR 20120263T HR P20120263 T HRP20120263 T HR P20120263T HR P20120263 T1 HRP20120263 T1 HR P20120263T1
Authority
HR
Croatia
Prior art keywords
dimethylcarbamoyl
piperazin
dichlorophenyl
cyclohexylamine
trans
Prior art date
Application number
HR20120263T
Other languages
English (en)
Inventor
Laszlovszky Istv�n
N�meth Gy�rgy
Andor Gy�rgy
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Publication of HRP20120263T1 publication Critical patent/HRP20120263T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/133Amines having hydroxy groups, e.g. sphingosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/452Piperidinium derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Spoj, naznačen time, da je to trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin i/ili njegove soli i/ili njegovi hidrati i/ili solvati i/ili polimorfi, koji su za uporabu u postupku liječenja shizofrenije s terapeutski učinkovitom količinom od 1,5; 3,0 ili 4,5 mg na dan. Patent sadrži još 8 patentnih zahtjeva.

Claims (9)

1. Spoj, naznačen time, da je to trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin i/ili njegove soli i/ili njegovi hidrati i/ili solvati i/ili polimorfi, koji su za uporabu u postupku liječenja shizofrenije s terapeutski učinkovitom količinom od 1,5; 3,0 ili 4,5 mg na dan.
2. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema zahtjevu 1, naznačen time, da je u obliku trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin hidroklorida i/ili njegovih hidrata i/ili solvata i/ili polimorfa.
3. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema zahtjevu 1 ili 2, naznačen time, da je terapeutski učinkovita količina podijeljena u jednu, dvije, tri ili četiri dnevne doze.
4. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja kognitivnih simptoma shizofrenije.
5. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja negativnih simptoma shizofrenije.
6. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja pozitivnih simptoma shizofrenije.
7. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja afektivnih i rezidualnih simptoma shizofrenije.
8. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja sekundarnih socijalnih i profesionalnih disfunkcija shizofrenije.
9. Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-N,N-dimetilkarbamoil-cikloheksilamin za uporabu prema bilo kojem od zahtjeva 1 do 3, naznačen time, da je za uporabu u postupku liječenja shizofreniformnog i shizoafektivnih poremećaja.
HR20120263T 2007-05-24 2012-03-22 Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje shizofrenije HRP20120263T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU0700369A HUP0700369A2 (en) 2007-05-24 2007-05-24 Use of (thio)-carbamoyl-cyclohexane derivatives in the manufacture of a medicament for the treatment in the manufacture of a medicament for the treatment of schizophrenia
PCT/HU2008/000051 WO2008142462A1 (en) 2007-05-24 2008-05-19 (thio) -carbamoyl-cyclohexane derivatives and method for treating schizophrenia

Publications (1)

Publication Number Publication Date
HRP20120263T1 true HRP20120263T1 (hr) 2012-04-30

Family

ID=47291297

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20120263T HRP20120263T1 (hr) 2007-05-24 2012-03-22 Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje shizofrenije

Country Status (28)

Country Link
US (1) US20100197666A1 (hr)
EP (1) EP2164492B1 (hr)
JP (1) JP2010527984A (hr)
KR (1) KR20150080016A (hr)
CN (2) CN101678018A (hr)
AT (1) ATE539750T1 (hr)
AU (1) AU2008252620B2 (hr)
CA (1) CA2687521C (hr)
CY (1) CY1113996T1 (hr)
DK (1) DK2164492T3 (hr)
EA (1) EA021962B1 (hr)
ES (1) ES2380083T3 (hr)
GE (1) GEP20135730B (hr)
HK (1) HK1137943A1 (hr)
HR (1) HRP20120263T1 (hr)
HU (1) HUP0700369A2 (hr)
IL (1) IL202047A (hr)
MX (1) MX2009012751A (hr)
MY (1) MY148257A (hr)
NZ (1) NZ582281A (hr)
PL (1) PL2164492T3 (hr)
PT (1) PT2164492E (hr)
RS (1) RS52206B (hr)
SI (1) SI2164492T1 (hr)
TW (1) TWI426906B (hr)
UA (1) UA101322C2 (hr)
WO (1) WO2008142462A1 (hr)
ZA (1) ZA200908282B (hr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
US20110059980A1 (en) * 2008-02-21 2011-03-10 Yasuaki Oobayashi Solid preparation for oral administration
SI2317852T1 (sl) 2008-07-16 2015-04-30 Richter Gedeon Nyrt. Farmacevtske formulacije, ki vsebujejo ligande dopaminskega receptorja
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP1200001A2 (en) 2012-01-02 2013-07-29 Gabor Dr Havas Wind motor with rotation axis substantially at right angle to wind direction with a multistage acceleration system
WO2014031162A1 (en) 2012-08-20 2014-02-27 Forest Laboratories Holdings Limited Crystalline form of carbamoyl-cyclohexane derivatives
HU231227B1 (hu) * 2012-11-29 2022-03-28 Richter Gedeon Nyrt. Transz-4-{2-[4-(2,3-diklórfenil)-piperazin-1-il]-etil}N,N-dimetilkarbamoil-ciklohexilamin skizofrénia negatív tüneteinek kezelésére
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6489341B1 (en) * 1999-06-02 2002-12-03 Sepracor Inc. Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
HU227534B1 (en) * 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
HU230748B1 (hu) 2007-05-11 2018-02-28 Richter Gedeon Nyrt Új piperazin só és előállítási eljárása
EP2155200B1 (en) * 2007-05-11 2016-12-07 Richter Gedeon Nyrt. Crystalline form of a carbamoyl-cyclohexane derivative

Also Published As

Publication number Publication date
EP2164492A1 (en) 2010-03-24
RS52206B (en) 2012-10-31
MY148257A (en) 2013-03-29
WO2008142462A1 (en) 2008-11-27
GEP20135730B (en) 2013-01-25
MX2009012751A (es) 2010-03-15
EP2164492B1 (en) 2012-01-04
AU2008252620B2 (en) 2014-06-05
AU2008252620A1 (en) 2008-11-27
DK2164492T3 (da) 2012-04-02
EA200971086A1 (ru) 2010-04-30
EA021962B1 (ru) 2015-10-30
TWI426906B (zh) 2014-02-21
IL202047A0 (en) 2010-06-16
US20100197666A1 (en) 2010-08-05
UA101322C2 (en) 2013-03-25
NZ582281A (en) 2012-05-25
PL2164492T3 (pl) 2012-06-29
CA2687521C (en) 2015-06-23
ATE539750T1 (de) 2012-01-15
IL202047A (en) 2015-02-26
JP2010527984A (ja) 2010-08-19
HUP0700369D0 (en) 2007-07-30
CA2687521A1 (en) 2008-11-27
TW201002325A (en) 2010-01-16
CY1113996T1 (el) 2016-07-27
CN101678018A (zh) 2010-03-24
PT2164492E (pt) 2012-04-10
SI2164492T1 (sl) 2012-04-30
HK1137943A1 (en) 2010-08-13
ZA200908282B (en) 2011-04-28
HUP0700369A2 (en) 2009-04-28
CN104546852A (zh) 2015-04-29
KR20150080016A (ko) 2015-07-08
ES2380083T3 (es) 2012-05-08

Similar Documents

Publication Publication Date Title
HRP20120263T1 (hr) Trans-4-{2-[4-(2,3-diklorofenil)-piperazin-1-il]-etil}-n,n-dimetilkarbamoil-cikloheksilamin za liječenje shizofrenije
ECSP088969A (es) Amino-imidazolones y su uso como medicamento para tratar deficiencias cognitivas, enfermedad de alzheimer, neurodegeneración y demencia
CY1121357T1 (el) Νεος ανοσοτροποποιητης και αντιφλεγμονωδεις ενωσεις
BR112015014007A2 (pt) composições de gama-hidroxibutirato e sua utilização para o tratamento de distúrbios
ECSP088970A (es) Amino-imidazolonas y su uso como medicamento para el tratamiento de la deficiencia cognitiva, la enfermedad de alzheimer, la neurodegeneración y la demencia
PH12013502359A1 (en) Carboxamide compounds and their use as calpain inhibitors
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
TW200806300A (en) New therapeutic combinations for the treatment of depression
MX2010005299A (es) Derivados de bis-(sulfonilamino) en terapia 066.
EA201490304A1 (ru) Циклические ингибиторы 11бета-гидроксистероид-дегидрогеназы 1
PT2139334E (pt) Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
NI200900203A (es) Sales novedosas de piperazina como antagonistas d3/d2.
MD20140119A2 (ro) Agenţi pentru tratarea afecţiunilor care implică modularea receptorilor de rianodină
UY30032A1 (es) Compuestos de cinolina, composiciones farmacéuticas que los contienen y procesos para la preparación y uso de los mismos
EA201100921A1 (ru) Соединения, фармацевтические композиции и способы их применения при лечении нарушений обмена веществ
PH12015501124B1 (en) Trans-4-{2-[4-(2,3-dichlorophenyl)-piperazin-1-yl]-ethyl}-n,n-dimethylcarbamoyl-cyclohexylamine for treating negative symptoms of schizophrenia
DOP2009000291A (es) Compuestos de quinolina adecuados para el tratamiento de trastornos que responden a la modulacion del receptor de serotonina 5-ht6
MX2009013885A (es) Derivados de quinolina fusionados utiles como moduladores de acido gamma-aminobutirico.
ECSP11011468A (es) Compuestos de n-fenil-(piperazinil u homopiperazinil)-bencensulfonamida o bencensulfonil-fenil-(piperazina u homopiperazina) adecuados para tratar trastornos que responden a la modulación del receptor de serotonina 5-ht6
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PE20151754A1 (es) Estra-1,3,5(10),16-tetraeno-3-carboxamidas para la inhibicion de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
AR059710A1 (es) Arilsulfonamidas sustituidas
EA201000633A1 (ru) КОМПОЗИЦИИ, СОДЕРЖАЩИЕ МОДУЛЯТОРЫ ФАКТОРА КОАГУЛЯЦИИ VIIa, И ИХ ПРИМЕНЕНИЕ
NZ582284A (en) Carbamoyl-cyclohexanes for treating acute mania
ECSP11010849A (es) Polimorfo b de la n-(2-aminofenil)-4-[n-(piridin-3-il) metoxicarbonilamino-metil]benzamida (ms-275)